Home > Insider Trading > Filing (0000947871-11-000350)

Filing Details

Accession Number:: 0000947871-11-000350
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-03-28 21:45:35
Reporting Period:: 2011-03-24

Filing Date:: 2011-03-28
Accepted Time:: 2011-03-28 21:45:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
897448	Amarin Corp Plc	AMRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1282930	L Carl Gordon	C/O Orbimed Advisors Llc 767 Third Avenue, 30Th Floor New York, NY 10017		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2011-03-24	22,800	$7.50	6,587,100	No	4	S	Indirect	See Footnotes
Ordinary Shares	Disposition	2011-03-24	200	$7.50	62,900	No	4	S	Indirect	See Footnotes
Ordinary Shares	Disposition	2011-03-25	56,400	$7.47	6,530,700	No	4	S	Indirect	See Footnotes
Ordinary Shares	Disposition	2011-03-25	500	$7.47	62,400	No	4	S	Indirect	See Footnotes
Ordinary Shares	Disposition	2011-03-28	92,200	$7.35	6,438,500	No	4	S	Indirect	See Footnotes
Ordinary Shares	Disposition	2011-03-28	900	$7.35	61,500	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

The Ordinary Shares (the "Shares") may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The reporting person is affiliated with OrbiMed Private Investments III, LP ("OPI III") and OrbiMed Associates III, LP ("Associates"), which hold the Shares reported herein. OrbiMed Capital GP III LLC ("Capital") is the sole general partner of OPI III. OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital and the sole general partner of Associates. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. OPI III and Associates have designated a representative, currently the reporting person, a member of Advisors, to serve on the Issuer's board of directors.
The reporting person does not have sole voting or investment power over the securities held by OPI III and Associates. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his affiliation with Advisors. The reporting person disclaims beneficial ownership of the Shares reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These Shares are beneficially owned by OPI III.
These Shares are beneficially owned by Associates.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $7.45 to $7.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $7.25 to $7.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.